I think we can break down the trials into the following with respect to cardioprotection and FTO inhibition:
1. Are the patients getting positive outcome (cancer/ symptom reduction) from the treatment and are the side effects as expected or below known adverse events.
2. Is that due to cardio protection and/ or FTO inhibition? How can we prove it?
3. Is it significant enough?
4. Are there any doubts in terms of safety, efficacy or the contribution of Bisantrene to the patient outcomes?
Anything else?
Cardioprotection thread, page-437
-
- There are more pages in this discussion • 216 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.94 |
Change
0.055(2.92%) |
Mkt cap ! $330.4M | |||
| Open | High | Low | Value | Volume |
| $1.89 | $1.96 | $1.85 | $333.0K | 174.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3105 | $1.94 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.95 | 7574 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |